Elbow Hemiarthroplasty Versus ORIF for Distal Humeral Fractures

Sponsor
Herlev and Gentofte Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04163172
Collaborator
(none)
44
1
2
155
0.3

Study Details

Study Description

Brief Summary

This is a randomized control trial comparing the outcome of ORIF (open reduction and internal fixation) with EHA (elbow hemiarthroplasty) for distal humeral fractures in patients aged 50 years or above.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Surgical treatment of distal humeral fracture with elbow hemiarthroplasty
  • Procedure: Surgical treatment of distal humeral fracture with double plating.
N/A

Detailed Description

Intraarticular distal humeral fractures AO/OTA type C2 and C3 pose a surgical challenge despite the evolution of surgical implants and techniques. Open reduction and internal fixation (ORIF) is often preferred as the first choice of treatment, but the results are varying, and sometimes disappointing. Total elbow arthroplasty (TEA) has been widely used for fractures that are not amenable to ORIF in elderly patients, but the mechanical complications remain a challenge, especially in active patients. Elbow hemiarthroplasty (EHA) provides a modern alternative that might avoid the mechanical complications and weight bearing restrictions related to the linked articulation in semiconstrained TEA. There are no studies comparing the results of EHA to that of TEA or ORIF, but case series have reported promising results.

In this study, forty-four patients with AO/OTA type C2 or C3 fractures of distal humerus will be randomized to either ORIF or EHA. The patients will be examined after the operation and at 3 months and 1, 2, 5 and 10 years after the surgery. The main objective of this study is to investigate the best treatment option for distal humeral fractures in patients aged 50 years or above. This can be of value to future patients sustaining these complicated fractures.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
44 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Elbow Hemiarthroplasty Versus Open Reduction and Internal Fixation for AO/OTA Type C2 and C3 Fractures of Distal Humerus in Patients Aged 50 Years or Above; a Randomized Controlled Trial
Actual Study Start Date :
Feb 1, 2020
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2032

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Elbow hemiarthroplasty

The Latitude anatomical hemiarthroplasty (WRIGHT -Memphis, Tennessee) for distal humeral fractures.

Procedure: Surgical treatment of distal humeral fracture with elbow hemiarthroplasty
Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)

Active Comparator: Open reduction and internal fixation

Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States) for distal humeral fractures.

Procedure: Surgical treatment of distal humeral fracture with double plating.
Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)

Outcome Measures

Primary Outcome Measures

  1. Oxford Elbow Score (OES) [2 years after surgery.]

    The OES is a 12-item patient-administrated questionnaire that measures the quality of life in patients with elbow disorder. There are three unidimensional domains: Elbow function, pain, and social-psychological status. Each question is answered on a 5-point scale with each question contributing equally to the total score.Thus, the total score ranges from 12-60, with 60 being the worst. For ease of presentation the score is converted to a scale from 0-48 with 48 being the best. The outcome can be interpreted based on a 48-point scale: 0 - 19 - poor; 20-29 - fair; 30-39 - good; and 40-48 - excellent. The Danish version which will be used in this study, has been translated and cultural adapted according to the guidelines by Guillemin, Bombardier and Beaton.

Secondary Outcome Measures

  1. Mayo Elbow Performance Score (MEPS) [3 months after surgery and 1, 2, 5, and 10 years after surgery.]

    The MEPS is a surgeon-administrated instrument that evaluates the outcome after elbow surgery. There are four domains including: Pain (0-45 points), range of motion (0-20 points), stability (0-10 points) and difficulties in daily activities (0-25 points).The outcome can be interpreted based on a 100 points scale: 0 - 60 - poor; 60-74 - fair; 75-89 - good; and 90-100 - excellent.

  2. Pain severity score (VAS) [3 months after surgery and 1, 2, 5, and 10 years after surgery.]

    Pain is answered on a visual analogue scale (VAS) ranging from 0 to 10, with 10 being the worst and 0 represents a pain free elbow.

  3. Range of motion [3 months after surgery and 1, 2, 5, and 10 years after surgery.]

    Measuring the flexion/extension and supination/pronation arcs in degrees.

  4. Patients satisfaction [3 months after surgery and 1, 2, 5, and 10 years after surgery.]

    Patients satisfaction of the treatment will be recorded using 5-items score with 1 being the worst and 5 represents a very satisfied patient.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Distal humeral fracture AO/OTA type C2 or C3 confirmed by plain radiographs with 2 perpendicular views and CT scan.

  2. ASA score 1-3 and physically fit for surgery.

  3. Age of 50 years or above.

Exclusion Criteria:
  1. Patients unable to follow the rehabilitation protocol or answer the Danish questionnaires because of physical or cognitive inabilities as evaluated by the recruiting surgeon.

  2. Significant elbow osteoarthritis as evaluated by the recruiting surgeon based on plain radiographs and CT scan.

  3. Fractures that are older than 6 weeks.

  4. Other associated elbow fractures.

  5. Pathological fractures or relevant elbow pathology.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Herlev and Gentofte University Hospital Copenhagen Denmark

Sponsors and Collaborators

  • Herlev and Gentofte Hospital

Investigators

  • Principal Investigator: Ali Al-Hamdani, MD, Herlev and Gentofte University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ali Al-Hamdani, Medical doctor, shoulder and elbow surgeon., Herlev and Gentofte Hospital
ClinicalTrials.gov Identifier:
NCT04163172
Other Study ID Numbers:
  • EVORI
First Posted:
Nov 14, 2019
Last Update Posted:
Aug 25, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2021